Columbia Chronic Lyme Disease Research Center
Message from the Director, Dr. Fallon:
This is both a disturbing and an exciting time in the world of Lyme disease.
Disturbing because the medical and public health communities have failed to stem the steady increase in the number
of cases of Lyme disease over the last 2 decades – with an expansion of over 35% between 2006-2007 alone.
Exciting because advances in medical technology are leading to breakthroughs in how we understand this
On the diagnostic front, proteomic studies offer the promise of identifying novel antigen markers that may
enhance the ability to distinguish active Lyme disease from past infection. Mass spectrometry-based
technologies, developed in response to biowarfare research, enable the rapid screening of fluids from the bodies of
ticks or humans for previously unidentified pathogens - pathogens in ticks, for example, other than Borrelia
burgdorferi, that may be causing human disease.
Genomic studies have begun to identify different strains of Borrelia, some of which may be more virulent, and
others which may target different organ systems. Immunologic studies are now identifying different host
immune responses to a spirochetal infection. These responses may be genetically driven, and predispose
certain individuals to develop chronic disease, and others to rapidly eradicate the initial infection.
Imaging studies in animals using immunoflourescent spirochetes now enable direct real-time visualization of the
spirochete’s course through the body. Human neuroimaging studies enable the identification of circuits of the
brain particularly affected among patients with chronic symptoms.
Treatment studies in animal models have definitively shown that the Borrelial spirochete is capable of
persisting in the animal host – even after aggressive antibiotic therapy. And treatment studies in
humans have identified tentative biomarkers that may serve to guide treatment selection. These immunologic
and neuroimaging biomarkers, if confirmed by additional prospective research, will provide clinicians with
new tools to distinguish those patients who are most likely to benefit from further antibiotics from those patients
who would require other non-antibiotic treatment approaches.
The pace of medical discovery has been accelerated by funding from the National Institutes of Health and by the
generous support of private donors – individuals and non-profit charitable organizations. Without the support
of private donors, the novel, pioneering pilot work that might lead to larger NIH-funded grants would never get
started. About 8 years ago, two organizations (Time for Lyme, Inc, and the Lyme Disease Association)
committed themselves to provide the cornerstone funds to establish a major new research Center at one of the
world’s foremost medical research institutions - Columbia University. This multi-disciplinary Research
Center, formally opened in 2007, is the first in the United States to focus research specifically on the problem of
chronic Lyme disease. It brings together experts in neurology, infectious disease, immunology, genetics,
neuroimaging, microbiology, neuropsychiatry, pathology, rheumatology, and public health.
As the number of typical and atypical cases of Lyme disease increases in the United States, so does the number
of patients who go on to develop chronic persistent symptoms. Lives are being profoundly altered by the bite
of a single tick. Our Center’s mission is to identify better diagnostic tests, safer and more effective treatments,
and clear biomarkers that will guide treatment selection. The vast intellectual and biotechnological
resources at the Columbia University Medical Center will continue to be tapped to achieve our goals, but our
researchers will need new funding to initiate new studies. We encourage you to read the content on our
website, send in suggestions for change, participate in a research study, and if able, send a contribution to support Lyme research.
Brian Fallon, MD
Director, Lyme and Tick-borne Diseases Research Center
1. Mission Statement
The Lyme and Tick-borne Diseases Research Center was established as the first academic research center in the
country to focus multidisciplinary research on chronic Lyme disease. In recognition that a growing number of
patients experience ongoing or relapsing symptoms after having been treated for Lyme disease and in recognition
that diagnostic tests are plagued by both false positive and false negative results and rarely provide definitive
information about the presence or absence of active infection, the mission of this center is to focus research on
identifying better diagnostic assays, better treatments, and a better pathophysiologic understanding of the
mechanisms of symptom persistence so as to enable the development of more effective treatments.
The Lyme and Tick-borne Diseases Research Center at the Columbia University Medical Center was established on
April 30, 2007 through a joint effort of Columbia University, Time for Lyme, Inc., and the Lyme Disease Association. Culminating many years of fund-raising efforts, the opening of
this Center represents a major achievement by many generous donors who banded together to lead the fight against
this rapidly spreading disease. There two charitable organizations recognized that patients with chronic
persistent symptoms were not included in most Lyme research studies even though these patients with later stage
symptoms were often the most disabled by the illness. These organizations also recognized that progress in
medical science only occurs through the support of well-designed research. To that end, these organizations
rallied their efforts to establish this Research Center at Columbia University. The establishment of this Center
is the first step toward ensuring that leading researchers at one of the foremost academic research centers in
the world are given the resources to focus their research efforts on unraveling the mysteries of chronic Lyme
disease.3. Research Team